(See Section 5.3) Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Page 42 • Optional core needle biopsy ; may be done anytime between PV2 and prior to dosing at Week 5 (CY1) only (S ee Section 5.3) 5.2.2.4 CRS -207 Post -chemotherapy Boost Vaccination (BV1, BV2) During the post -chemotherapy boost vaccination (BV) period, all subjects (Cohorts 1 and 2) will be administered two infusions of CRS -207 3 weeks apart at least 3 weeks after the last chemotherapy cycle. Cohort 2 only will receive a low -dose Cy administration one day prior to each CRS -207 boost vaccination by i.v. infusion at the dose of 200 mg/m2 in 100 mL normal saline over 30 minutes. Subjects must receive at least 2 cycles of pemetrexed and cisplatin to continue to receive CRS -207 (with or without Cy) after chemotherapy. CRS -207 will be administered and moni tored and the same procedures conducted as on Day 1 in Section 5.2.2.1 and Day 2 in Section 5.2.2.2. One week (7 ± 1 days) after each CRS -207 infusion, subjects will be contacted by phone to assess AEs and concomitant medications. In addition to those procedures listed in Section 5.2.2.1, prior to the first study drug dosing ( Cy or CRS -207) at boost vaccination (BV1) following chemotherapy, the following procedures will be conducted: • CD4 count. Blood draw may be done up to 3 days prior to CRS -207 dosing (Cohort 1) or 2 days prior to Cy for subjects receiving Cy (Cohort 2). • Spiral CT scan of thorax and abdomen with optional FDG -PET scan.